Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by ...

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...

Q2 2025 Earnings Call Transcript August 12, 2025 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration's approval of the company's Iron Sucrose Injection, USP, the first generic version of ...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...